Showing results (71-80 of 126) with videos related to
Sort By:
Pageof 13
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.Blood Cancer Journal|February 17, 2021
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosisGiovanni Palladini, Bruno Paiva, Ashutosh Wechalekar, et al.The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.The Lancet. Haematology|July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.Haematologica|July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. HydePellegrino Musto, Monika Engelhardt, Jo Caers, et al.Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.Blood|October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsHervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.Pageof 13